# Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study

> **NCT05438758** · PHASE2 · WITHDRAWN · sponsor: **Zylorion Health**

## Conditions studied

- Treatment Resistant Major Depressive Disorder

## Interventions

- **BEHAVIORAL:** Almond Therapy
- **DRUG:** Intranasal ketamine (Esketamine)
- **BEHAVIORAL:** Treatment as Usual

## Key facts

- **NCT ID:** NCT05438758
- **Lead sponsor:** Zylorion Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-01-15
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn by Sponsor
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438758, "Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05438758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*